학술논문

Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study
Document Type
Article
Source
In The Lancet Oncology May 2023 24(5):496-508
Subject
Primary Research
Articles
Language
ISSN
1470-2045